For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
Follicle Stimulating Hormone (FSH) is a 35.5 kDa heterodimer (alpha and beta unit) glycoprotein that is synthesized by the anterior pituitary gland and regulates the fertility processes. The FSH molecule shares a common subunit (alpha chain) with Luteinizing Hormone (LH), Thyroid-Stimulating Hormone (TSH), and Human Chorionic Gonadotropin (hCG) while the beta subunit of FSH varies from LH, TSH, and hCH. The beta subunit is known to carry out specific biological activities on the ovary and testis. The level of FSH in serum is an excellent indicator for determining the status of oocyte maturation and follicle development in female. Infertility in females is often associated with mutations of the FSH gene resulting in reduced FSH synthesis. FSH is measured in International Units (IU). For recombinant FSH, one IU corresponds to approximately 0.065 to 0.075 µg of protein.
|Assay Target Class||Hormone|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||500 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.